Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLNEPA: Olanzapine, Netupitant and Palonosetron for CINV in Breast Cancer
NCT04669132Phase 2Completed
- Sponsor
- IBCC Oncologia
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olanzapine, netupitant, palonosetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by IBCC Oncologia. Started Dec 2020; status: completed.
02
Drugs
olanzapinenetupitantpalonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT04669132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04669132.